Arrowhead Pharmaceuticals, Inc.

This stock has a reasonable momentum. Arrowhead Pharmaceuticals, Inc. is not very popular among insiders. Arrowhead Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that...
ARWR Fundamental Data by TradingView

News

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Business Wire Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as...\n more…

The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable
The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable

Simply Wall St Research Arrowhead Pharmaceuticals' (Nasdaq:ARWR) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.\n more…

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Investopedia Headlines Getty Images\n\n Key TakeawaysArrowhead Pharmaceuticals reported a Phase-3 study of its medicine for a rare genetic disorder met all its primary endpoints and key secondary endpoints.The...\n more…

Arrowhead Pharmaceuticals: Strong Buy Rating on Robust Clinical Data and Promising Commercial Prospects
Arrowhead Pharmaceuticals: Strong Buy Rating on Robust Clinical Data and Promising Commercial Prospects

TipRanks Financial Blog In a report released yesterday, Keay Nakae from Chardan Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR - Research Report), with...\n more…

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Business Wire Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe...\n more…

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Business Wire Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology...\n more…